http://www.ncbi.nlm.nih.gov/pubmed/24739760

The abstract of the recently mentioned study has appeared:

QUOTE:

Sci Transl Med. 2014 Apr 16;6(232):232ra52.
doi: 10.1126/scitranslmed.3008517.

An orally available, small-molecule polymerase inhibitor shows efficacy
against a lethal morbillivirus infection in a large animal model.

Krumm SA1, Yan D, Hovingh ES, Evers TJ, Enkirch T, Reddy GP, Sun A,
Saindane MT, Arrendale RF, Painter G, Liotta DC, Natchus MG, von
Messling V, Plemper RK.

Abstract
Measles virus is a highly infectious morbillivirus responsible for
major morbidity and mortality in unvaccinated humans. The related,
zoonotic canine distemper virus (CDV) induces morbillivirus disease
in ferrets with 100% lethality. We report an orally available,
shelf-stable pan-morbillivirus inhibitor that targets the viral RNA
polymerase. Prophylactic oral treatment offerrets infected intranasally
with a lethal CDV dose reduced viremia and prolonged survival. Ferrets
infected with the same dose of virus that received post-infection
treatment at the onset of viremia showed low-grade viral loads,
remained asymptomatic, and recovered from infection, whereas control
animals succumbed to the disease. Animals that recovered also mounted
a robust immune response and were protected against rechallenge with
a lethal CDV dose. Drug-resistant viral recombinants were generated
and found to be attenuated and transmission-impaired compared to the
genetic parent virus. These findings may pioneer a path toward an
effective morbillivirus therapy that could aid measles eradication by
synergizing with vaccination to close gaps in herd immunity due to
vaccine refusal.

END QUOTE

Hopefully, Yahoogroups is not losing messages today as it did
yesterday. I just was not up to rewriting one today...

[Posted in FML 8092]